Applied Cannabis Research, Industry Heavyweights & Medical Networks Join For Australia’s Largest Medical Cannabis Study

Study is Australia’s most comprehensive to date in the medicinal cannabis sector, recruiting 20,000 patients nationwide

SYDNEY, NSW, AUSTRALIA, October 25, 2020 /EINPresswire.com/ — Applied Cannabis Research (ACR), a Southern Cannabis Holdings company, is extremely excited to announce that it is launching Australia’s largest observational study ever undertaken for medical cannabis. ACR will lead the study in conjunction with Australia’s medical community and key industry partners such as Althea Group Holdings, Cronos Australia, Cymra Life Sciences, Medcan Australia and Cann Global.

Working with clinical collaborators from major clinics and hospitals, the Cannabinoid Medicine Observational Study (CMOS) will collect data from 20,000 patients nationwide to assess the safety and efficacy of medicinal cannabis products for a range of refractory conditions including fibromyalgia, chronic pain syndromes, PTSD,…